Rivastigmine Multi-Day Transdermal Patch (Rivastigmine MD) is a twice-weekly innovative patch formulation of Rivastigmine for the treatment of mild to moderate dementia associated with Alzheimer ...

Luye Pharma Group today announced that marketing approval for its innovative formulation Rivastigmine Twice Weekly Transdermal Patch has been granted by the Japanese Ministry of Health, Labour and ...

Rivastigmine is a first-line drug in the treatment of dementia associated with Alzheimer's disease and is currently marketed worldwide. About Rivastigmine Multi-Day Transdermal Patch ...

In elderly patients with cognitive dysfunction undergoing surgery for hip fracture, perioperative application of the rivastigmine patch reduced incidence postoperative delirium. VANCOUVER, BC—In ...

GUILDFORD, England, Sept. 23, 2021 /PRNewswire/ -- Luye Pharma Group today announced that marketing approval for its innovative formulation Rivastigmine Multi-Day Transdermal Patch (Rivastigmine ...

Patients suffering from mild to moderately severe Alzheimer’s disease can now receive their medication transdermally following the European Commission’s approval of Novartis’ Exelon (rivastigmine) ...

TOKYO, March 31, 2025 /PRNewswire/ -- Luye Pharma Group today announced that marketing approval for its innovative formulation Rivastigmine Twice Weekly Transdermal Patch has been granted by the ...